Washington reached a $518 million settlement with drug distributors McKesson Corp., AmerisourceBergen Corp. and Cardinal Health, ending a months-long trial over the companies’ alleged role in fueling the opioid epidemic in the state, the three companies announced on May 3.
San Francisco squared off on April 25 against Walgreens Boots Alliance and three other companies accused of fueling an opioid crisis in the city, the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.
Florida reached more than $878 million in settlements with CVS Health Corp. and three drug companies to resolve claims and avert a trial in April over their roles in fueling an opioid epidemic in the third most populous U.S. state.
Rhode Island was set to square off on March 14 against Teva Pharmaceutical Industries Ltd., as a multibillion-dollar trial begins over whether the Israeli company contributed to an opioid crisis that has caused more than 500,000 deaths over the past two decades.
The three largest U.S. drug distributors and drugmaker Johnson & Johnson agreed to finalize a proposed $26 billion settlement resolving claims by states and local governments that they helped fuel the U.S. opioid epidemic.
The three largest U.S. drug distributors and drugmaker Johnson & Johnson agreed to pay $590 million to resolve claims by Native American tribes that the companies fueled an opioid epidemic in their communities, according to court filings.
U.S. cities and counties have embraced a proposed settlement worth up to $26 billion resolving lawsuits alleging three large drug distributors and drugmaker Johnson & Johnson fueled the U.S. opioid epidemic, lawyers behind the deal said on January 26, increasing the odds that it will move forward.
Rhode Island on Jan. 25 reversed course and threw the state’s support behind a $21 billion nationwide settlement it originally declined to back resolving lawsuits alleging that three large drug distributors fueled the deadly U.S. opioid epidemic.
Generics giant Teva Pharmaceuticals reached a $15 million agreement with the state of Louisiana to settle claims against the company over its marketing of opioid products that contributed to the opioid addiction epidemic that swept across the United States and claimed the lives of hundreds of thousands of people.
At least six U.S. states, including Georgia, did not fully sign on to a proposed $26 billion settlement with three drug distributors and Johnson & Johnson – which have been accused of fueling the nation’s opioid epidemic – according to the states’ attorneys general.